Tyrosine kinase inhibitors (TKIs) are widely used in cancer therapy yet are strongly associated with acute and chronic cardiotoxicity in patients. There is a critical need to advance our understanding of the pathophysiology that underlies TKI-mediated cardiotoxicity, and central to this is the use of reproducible and relevant preclinical models, which are employed in the evaluation of TKIs across the drug discovery pipeline. W...